Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 10;15(1):12268.
doi: 10.1038/s41598-025-96425-5.

A systematic qualitative review of ethical issues in open label placebo in published research

Affiliations

A systematic qualitative review of ethical issues in open label placebo in published research

Mélina Richard et al. Sci Rep. .

Abstract

Open-label placebos (OLPs), which are transparently administered inert treatments, have gained increasing attention in the research community. They have the potential to harness placebo effects without deceiving the patient. The purpose of this study was to examine and synthesize prior research discussing ethical issues in OLPs. A systematic qualitative literature review was conducted (last search on January 2023) across multiple databases (e.g., MEDLINE, Embase, PsycInfo) using keywords related to OLPs. Publications were screened and assessed for eligibility. Seventeen articles explicitly addressing OLP ethics were included. Data were extracted and thematically analyzed following established qualitative content analysis procedures. 37 distinct ethical issues were identified, grouped into five overarching themes: (1) Sociocultural and Contextual Factors, (2) Implementation and Logistics, (3) Informed Consent, (4) Patient Health Behavior and Dynamics, and (5) Therapeutic Relationship. Frequently mentioned concerns focused on uncertainty of OLP efficacy, the need for further research, and complexities of dose-extending OLPs. The effective integration of OLPs into healthcare necessitates thoughtful consideration and responsible communication. This analysis shows that demonstrating the efficacy of OLPs becomes pivotal for their widespread adoption, underscoring the necessity for additional research to validate their effectiveness. This review was pre-registered on January 26th, 2023, in the Open Science Framework Registry under the identifier: DOI https://doi.org/10.17605/OSF.IO/R6NKG .

Keywords: Bioethics; OLP; Open label placebos; Placebo research; Systematic qualitative review.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests. Ethical approval and informed consent: This article does not contain any studies with human participants performed by any of the authors.

Figures

Fig. 1
Fig. 1
PRISMA flowchart overview.

Similar articles

References

    1. Blease, C., Colloca, L. & Kaptchuk, T. J. Are open-label placebos ethical? Informed consent and ethical equivocations. Bioethics30, 407–414. 10.1111/bioe.12245 (2016). - PMC - PubMed
    1. Bartley, H., Clarke, S. & Ryan, C. Ethical frameworks for the use of placebos in clinical practice: a scoping review. BMC Med. Ethics22, 56. 10.1186/s12910-021-00631-9 (2021). - PubMed
    1. Foddy, B. A duty to deceive: placebos in clinical practice. Am. J. Bioethics9, 4–12. 10.1080/15265160903318350 (2009). - PubMed
    1. Hróbjartsson, A. & Gøtzsche, P. C. Placebo interventions for all clinical conditions. Cochrane Database Syst. Rev.2010, 003974. 10.1002/14651858.CD003974.pub3 (2010). - PMC - PubMed
    1. Miller, F. G. & Colloca, L. The legitimacy of placebo treatments in clinical practice: evidence and ethics. Am. J. Bioethics9, 39–47. 10.1080/15265160903316263 (2009). - PubMed

Publication types

LinkOut - more resources